Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...
Investor's Business Daily on MSN18h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy PointsNetflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
She names Eli Lilly (LLY) as one other stock that is "treading water" but in a different manner than tech. Eli Lilly could potentially see $150 to $200 more in this stock coming up, Schneider ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback